Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

Back to Search
Print
Bookmark Trial

NCT04065633

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
New Haven Clinical Research Unit
New Haven, Connecticut, 06511, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Dermatitis, Atopic
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any condition possibly affecting drug absorption (eg, gastrectomy).


- History of human immunodeficiency virus (HIV) infection, hepatitis B, or
hepatitis


- Evidence or history of clinically significant dermatological condition (eg,
atopic dermatitis or psoriasis) .History of tuberculosis (TB) (active or latent)
or inadequately treated TB infection.


- History of chronic infections, history of recurrent infections, history of latent
infections, .History of disseminated herpes zoster, or disseminated herpes
simplex, or recurrent localized dermatomal herpes zoster.


- history of malignancies with the exception of adequately treated or excised
non-metastatic basal cell or squamous cell cancer of the skin, or cervical
carcinoma in situ

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Dermatitis, AtopicDrug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
NCT03634345
  1. Brussels,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Dermatitis, AtopicCrisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
NCT03233529
  1. Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Dermatitis, AtopicStudy Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
NCT03575871
  1. New York, New York
  2. Carlton, Victoria
  3. Nachod,
  4. Blankenfelde-Mahlow,
  5. Anaheim, California
  6. Rolling Hills Estates, California
  7. Santa Monica, California
  8. Colorado Springs, Colorado
  9. Colorado Springs, Colorado
  10. Jacksonville, Florida
  11. Jacksonville, Florida
  12. Jacksonville, Florida
  13. Orlando, Florida
  14. Tampa, Florida
  15. Caldwell, Idaho
  16. Nampa, Idaho
  17. Baton Rouge, Louisiana
  18. Boston, Massachusetts
  19. Saint Joseph, Missouri
  20. Wilmington, North Carolina
  21. Columbus, Ohio
  22. Gahanna, Ohio
  23. Memphis, Tennessee
  24. Memphis, Tennessee
  25. Austin, Texas
  26. Houston, Texas
  27. Franklin, Virginia
  28. Norfolk, Virginia
  29. Maroubra, New South Wales
  30. Benowa, Queensland
  31. Woolloongabba, Queensland
  32. East Melbourne, Victoria
  33. Parkville, Victoria
  34. Parkville, Victoria
  35. Dupnitsa,
  36. Gabrovo,
  37. Sofia,
  38. Sofia,
  39. Sofia,
  40. Sofia,
  41. Vancouver, British Columbia
  42. Winnipeg, Manitoba
  43. North York, Ontario
  44. Oshawa, Ontario
  45. Richmond Hill, Ontario
  46. Toronto, Ontario
  47. Sherbrooke, Quebec
  48. Beijing, Beijing
  49. Chongqing, Chongqing
  50. Shenzhen, Guangdong
  51. Beijing,
  52. Tianjin,
  53. Nachod,
  54. Nachod,
  55. Praha 1,
  56. Praha 2,
  57. Svitavy,
  58. Svitavy,
  59. Bad Bentheim,
  60. Berlin,
  61. Frankfurt,
  62. Hamburg,
  63. Münster,
  64. Schwerin,
  65. Budapest,
  66. Budapest,
  67. Debrecen,
  68. Kecskemet,
  69. Szolnok,
  70. Yokohama, Kanagawa
  71. Kamimashiki-gun, Kumamoto
  72. Neyagawa, Osaka
  73. Sakai, Osaka
  74. Edogawa-ku, Tokyo
  75. Nakano-ku, Tokyo
  76. Fukuoka,
  77. Saitama,
  78. Bucheon-si, Gyeonggi-do
  79. Bupyeong-gu, Incheon
  80. Jung-gu, Incheon
  81. Daegu,
  82. Gwangju,
  83. Seoul,
  84. Seoul,
  85. Seoul,
  86. Seoul,
  87. Seoul,
  88. Jelgava,
  89. Riga,
  90. Riga,
  91. Riga,
  92. Riga,
  93. Bialystok,
  94. Białystok,
  95. Krakow,
  96. Kraków,
  97. Kraków,
  98. Lodz,
  99. Lublin,
  100. Szczecin,
  101. Warszawa,
  102. Warszawa,
  103. Warszawa,
  104. Warszawa,
  105. Wroclaw,
  106. Wrocław,
  107. Plymouth, Devon
  108. Blackpool, Lancashire
  109. Cannock, South Staffordshire
  110. Barnsley, South Yorkshire
  111. Bristol,
  112. Manchester,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Dermatitis, AtopicStudy to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
NCT03349060
  1. Calgary, Alberta
  2. Calgary, Alberta
  3. Calgary, Alberta
  4. Surrey, British Columbia
  5. Surrey, British Columbia
  6. Vancouver, British Columbia
  7. Winnipeg, Manitoba
  8. Markham, Ontario
  9. Peterborough, Ontario
  10. Richmond Hill, Ontario
  11. Richmond Hill, Ontario
  12. Toronto, Ontario
  13. Montreal, Quebec
  14. Sherbrooke, Quebec
  15. Kutna Hora,
  16. Kutna Hora,
  17. Ostrava - Poruba,
  18. Ostrava - Poruba,
  19. Praha 1,
  20. Praha 2,
  21. Usti nad Labem,
  22. Usti nad Labem,
  23. Luebeck, Schleswig-holstein
  24. Münster,
  25. Kecskemet, Bács-kiskun
  26. Debrecen,
  27. Miskolc,
  28. Pecs,
  29. Katowice,
  30. Katowice,
  31. Katowice,
  32. Katowice,
  33. Lodz,
  34. Lodz,
  35. Ostrowiec Swietokrzyski,
  36. Warszawa,
  37. Birmingham, Alabama
  38. Encinitas, California
  39. San Diego, California
  40. San Diego, California
  41. Santa Monica, California
  42. Coral Gables, Florida
  43. Largo, Florida
  44. Tampa, Florida
  45. Savannah, Georgia
  46. Skokie, Illinois
  47. Indianapolis, Indiana
  48. Indianapolis, Indiana
  49. Boston, Massachusetts
  50. Detroit, Michigan
  51. Troy, Michigan
  52. Saint Joseph, Missouri
  53. Oklahoma City, Oklahoma
  54. Tulsa, Oklahoma
  55. Portland, Oregon
  56. Charleston, South Carolina
  57. Charleston, South Carolina
  58. Arlington, Texas
  59. Houston, Texas
  60. San Antonio, Texas
  61. Norfolk, Virginia
  62. Lakewood, Washington
  63. Tacoma, Washington
  64. Tacoma, Washington
  65. Tacoma, Washington
  66. Maroubra, New South Wales
  67. Maroubra, New South Wales
  68. Upper Mount Gravatt, Queensland
  69. Woolloongabba, Queensland
  70. Camberwell, Victoria
  71. Carlton, Victoria
  72. Carlton, Victoria
  73. East Melbourne, Victoria
  74. Parkville, Victoria
  75. Richmond, Victoria
  76. Bad Bentheim,
  77. Berlin,
  78. Berlin,
  79. Dresden,
  80. Erlangen,
  81. Kiel,
  82. Munich,
  83. Schwerin,
  84. Plymouth, Devon
  85. London, Greater London
  86. Sheffield, South Yorkshire, England
  87. Sheffield, South Yorkshire
  88. Dudley,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
Official Title  ICMJE A PHASE 1, OPEN LABEL, SINGLE-DOSE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF A COMMERCIAL TABLET FORMULATION OF PF-04965842 RELATIVE TO THE PHASE III TABLET FORMULATION UNDER FASTING CONDITIONS AND THE EFFECT OF FOOD ON THE RELATIVE BIOAVAILABILITY OF THE COMMERCIAL TABLET FORMULATION IN HEALTHY PARTICIPANTS
Brief Summary

Part A

  • To measure and compare the amount of study drug in the blood after a single 200 mg dose of study drug given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions
  • To measure and compare the amount of study drug in the blood after a single 200 mg dose given as the variant Phase 3 tablet formulation and the Phase 3 tablet formulation under fasting conditions
  • To estimate the effect of food on the amount of study drug in the blood after a single 200 mg dose of the commercial formulation

Part B

? To measure and compare the amount of study drug in the blood after a single 200 mg dose given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions

Parts A & B

  • To collect samples for genotyping (CYP2C19 and CYP2C9 - enzymes that metabolize [break down] certain medications)

    o Genotyping is the collection of a small sample of blood that contains your genes

  • To evaluate the safety and tolerability of the study drug after single 200 mg doses of the three different formulations given to healthy participants
  • To measure the amount of study drug in the blood after single doses of the different formulations
  • To collect exploratory samples for biobanking o Biobanking is the collection and storage of blood samples for possible future testing
Detailed Description

The purpose of this study in healthy participants is to estimate the bioavailability (BA) of the commercial formulation of PF-04965842 and a variant formulation with slower dissolution relative to the Phase 3 formulation, to demonstrate the bioequivalence (BE) of the commercial formulation relative to the Phase 3 formulation, and to estimate the effect of food on the BA of the commercial formulation. This study consists of 2 parts: Part A is to estimate the relative BA (rBA) of single 200 mg doses of the commercial tablet formulation of PF-04965842 and a variant formulation of slower dissolution rate compared to the Phase 3 tablet formulation. The effect of food on the BA of the commercial tablet formulation will also be evaluated. Part B is to establish BE between the Phase 3 and commercial formulations. The study will follow a staged approach as the sample size for BE cannot be determined with currently available information.

Therefore, it is proposed to assess the maximum observed concentration (Cmax) and area under the curve (AUC) ratios between the Phase 3 and commercial formulations as well as the within-participant variability of Cmax and AUC values determined in Part A. Based on the results from Part A, the sample size of Part B will be determined and the decision to proceed to Part B will be made.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
This is a Phase 1 randomized, open label, single-dose, crossover study in healthy participants to estimate the rBA of the commercial formulation of PF-04965842 (Test formulation 1) and the variant formulation with slower dissolution (Test formulation 2) compared to the Phase 3 formulation (Reference formulation), to demonstrate the BE of the commercial formulation relative to the Phase 3 formulation, and to estimate the effect of food on the rBA of the commercial formulation after a single 200 mg oral dose.
Masking: None (Open Label)
Primary Purpose: Other
Condition  ICMJE Dermatitis, Atopic
Intervention  ICMJE
  • Drug: P3-Fast
    200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
  • Drug: Comm-Fast
    200 mg PF-04965842 commercial tablet formulation under fasted conditions
  • Drug: Vari-Fast
    200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
  • Drug: Comm-Fed
    200 mg PF-04965842 commercial tablet formulation under fed conditions
Study Arms  ICMJE
  • Experimental: Part A sequence 1
    Interventions:
    • Drug: P3-Fast
    • Drug: Comm-Fast
    • Drug: Vari-Fast
    • Drug: Comm-Fed
  • Experimental: Part A sequence 2
    Interventions:
    • Drug: P3-Fast
    • Drug: Comm-Fast
    • Drug: Vari-Fast
    • Drug: Comm-Fed
  • Experimental: Part B sequence 1
    Interventions:
    • Drug: P3-Fast
    • Drug: Comm-Fast
  • Experimental: Part B sequence 2
    Interventions:
    • Drug: P3-Fast
    • Drug: Comm-Fast
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 20, 2019)		46
Original Estimated Enrollment  ICMJE
 (submitted: August 20, 2019)		64
Actual Study Completion Date  ICMJE December 14, 2019
Actual Primary Completion Date December 14, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)

Exclusion Criteria:

  • Any condition possibly affecting drug absorption (eg, gastrectomy).

    • History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis
    • Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) .History of tuberculosis (TB) (active or latent) or inadequately treated TB infection.
    • History of chronic infections, history of recurrent infections, history of latent infections, .History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.
    • history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04065633
Other Study ID Numbers  ICMJE B7451032
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
Principal Investigator:Sylvester Pawlak, APRNPfizer
PRS Account Pfizer
Verification Date January 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP